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Determinants of serum 1,25(OH)2D levels in renal disease. Serum
l,25(OH)2D and factors related to its production were studied in 39
patients with various degrees of renal insufficiency. Serum 1 ,25(OH)2D
levels correlated positively with 1/serum creatinine values (r = 0.54, P
<0.001) and negatively with serum phosphorus (r = —0.39, P < 0.02)
and age (r = —0.33, P < 0.05). There was no significant correlation
between 1 ,25(OH)2D levels and serum calcium or calcitonin or PTH,
although the logarithm of PTH correlated inversely with I ,25(OH)2D
levels (r =
—0.47, P < 0.01). Patients who had normal or supranormal
I ,25(OH)2D levels despite low GFR tended to have low serum phospho-
rus values. Serum levels of bone Gla protein (BGP), a biochemical
marker for bone metabolism, correlated negatively with 1/serum creati-
nine (r =
—0.39, P < 0.02) and positively with PTH (r = 0.57, P <
0.001) and age (r = 0.33, P < 0.05). Prophylaxis with l,25(OH)2D
should be considered in patients with significantly decreased serum
1 ,25(OH)2D levels, as seem to occur when serum creatinine is > 4.0
mg/dl. However, despite the statistically significant correlation between
serum I ,25(OH)2D and 1/serum creatinine, direct measurement should
be used to ascertain the serum concentration of I ,25(OH)2D in chronic
renal insufficiency.
Determinants des concentrations sériques de 1 ,25(OH)2D dans les
maladies rénales. La 1,25(OH)2D sérique et les facteurs relies a sa
production ont été étudiés chez 39 malades a différents degrés d'insuffi-
sance rénale. Les concentrations de I ,25(OH)2D sérique étaient positi-
vement corrélées avec 1/créatininémie (r = 0.54, P < 0.001) et
négativement avec Ia phosphorémie (r = —0.39, P < 0.02) et l'age (r =
—0.33, P < 0.05). Il n'y avait pas de correlation significative entre les
concentrations de 1 ,25(OH)2D et le calcium, Ia calcitonine ou Ia PTH
serique, bien que le logarithme de la PTH soit inversement correlé avec
les concentrations 1,25(OH)2D (r =
—0.47, P < 0.01). Des malades qui
avaient des concentrations de 1 ,25(OH)2D normales ou au-dessus de la
normale malgré une GFR basse avaient tendance a avoir des valeurs de
phosphoremie basses. Les concentrations sériques de Gla protCine
osseuse (BGP), un marqueur biochimique du mCtabolisme osseux,
étaient corrClCes négativement avec 1/créatininCmie (r =
—0.39, P <
0.02) et positivement avec Ia PTH (r = 0.57, P < 0.001) et l'âge (r =
0.33, P < 0.05). Le traitement prophylactique avec la 1 ,25(OH)2D doit
être considCrC chez des malades avec une diminution significative des
concentrations sériques de I ,25(OH)2D, qui semblent se produire
lorsque La créatininémie est au-dessus de 40 mg/litre. Cependant,
malgré Ia correlation statistiquement significative entre Ia 1 ,25(OH)2D
sCrique et l/créatininémie, des mesures directes doivent être utilisCes
pour préciser Ia concentration sCrique de I ,25(OH)2D dans l'insuffi-
sance rCnale chronique.
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The impaired synthesis of 1 ,25(OH)2D is a major factor in the
development of renal osteodystrophy. This hormonal form of
vitamin D is produced by la-hydroxylation of 25(OH)D3 in the
renal cortex [1, 2]. Hence, serum 1,25(OH)2D levels are re-
duced in patients with endstage renal failure [3—5] and practical-
ly undetectable in the anephric patients [3, 6, 7]. Reduced
serum 1 ,25(OH)2D leads to decreased intestinal absorption of
calcium [8], decreased calcemic response to the skeletal action
of parathyroid hormone [9, 10], and defective bone mineraliza-
tion [11]. The resultant hypocalcemia, also produced by phos-
phate retention [12—14], leads to secondary hyperpara-
thyroidism [15, 16] which causes further skeletal disease.
Calcitonin levels are often increased in renal failure [17] as are
levels of bone Gla protein (BGP) [18, 19], a component protein
of bone whose serum concentrations reflect bone metabolism
[18, 19] and whose production is increased by I ,25(OH)2D [20,
21]. Several studies have shown that treatment of patients with
renal osteodystrophy with 1 ,25(OH)2D results in a decrease in
bone pain [22], plasma alkaline phosphatase [23, 241, and serum
parathyroid hormone (PTH) levels [23—25] and improvement of
bone histology [26].
The present study was undertaken to examine the relation-
ships among 1,25(OH)2D levels, renal function, and other
factors and minerals in patients with variable degrees of renal
failure.
Methods
Patients. Adult patients were studied from the outpatient
renal clinics of the San Diego Veterans Administration Medical
Center and the Naval Regional Medical Center, San Diego,
California. Inclusion criteria were (1) serum creatinine above
1.5 mgldl, (2) 24-hr urine creatinine clearance below 80% of
normal, and (3) parenchymal renal disease as suggested by
proteinuria or proven by renal biopsy. A total of 39 patients
were selected who fulfilled at least one of the above criteria and
did not show a rapid decline of renal function while being
followed in the renal clinic. There were 28 males and 11 females
with a mean age of 55.4 2.3 (sEM) years (range, 29 to 88). The
presumed etiologies of their primary renal diseases are listed in
Table 1. Seven patients were receiving phosphate-binding
agents. However, no patient was receiving any vitamin D
preparation (except as contained in multivitamins), including
25-hydroxycholecalciferol, 1 ,25-dihydroxycholecalciferol, or
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Table 1. Diagnosis of renal diseases in the studied subjects
Nephrosclerosis
Arterial embolic disease
Reflux nephropathy
Obstructive uropathy
Analgesic nephropathy
Chronic interstitial nephritis
Tuberculosis
Polycystic kidney disease
Diabetic nephropathy
Mesangioproliferative glomerulonephritis
Membranous glomerulopathy
Lupus nephritis
Gold nephropathy
IgA glomerulonephritis
Other chronic glomerulonephritis
Unknown
Total
calcium supplements. All blood samples were drawn by veni-
puncture the morning after an overnight fast.
Assays. Serum i,25(OH)2D levels were measured by the
cytoreceptor assay [27, 28]. The normal adult mean (± SE) for
this procedure is 33.8(± 1.2) pg/mi. Calcitonin (CT) was mea-
sured by radioimmunoassay as previously described [17, 29].
PTH and bone Gla (gamma-carboxyglutamic acid)-containing
protein (BGP) were measured by modifications [18, 301 of
previously described radioimmunoassays (Reitz, Schwartz,
Rowe, Weaver, Beallo, Catherwood, and Deftos, unpublished
observations) [311. For PTH, an antibody of specificity for the
middle region of the hormone (mid-molecule assay) was used
[31, 32]. For these immunoassays, the respective upper limit of
normals are 100 pg/mi for CT, 150 pglml for PTH, and 20
pmoles/ml for BGP [17, 18, 29—31]. The interassay variations
for these assay procedures are 15%. Serum levels of creati-
nine (Cr), calcium (Ca), and phosphorus (P) were measured by
an analyzer (Technicon SMAC) with normal ranges of 0.8 to 1.2
mg/dl for creatinine, 9.0 to 10.6 mg!dl for calcium, and 2.5 to 4.5
mg/dl for phosphorus.
Statistical analysis. The reciprocal value of serum creatinine
concentration was used in the present study as an index of renal
function. This value has been demonstrated previously in
patients with a variety of renal diseases to decline linearly as
chronic renal failure progressed [33].
Linear regression analysis by least-squares fit was used to
determine the correlation between two variables. Multiple
regression analysis was applied to correlate 1,25(OH)2D levels
with several variables. The confidence of correlation was
determined by the correlation coefficient (r). Differences of
values between two groups were evaluated by Student's un-
paired t test. All values are reported as mean SEM.
Results
Tables 2 and 3 summarize the biochemical measurements and
their correlations.
Figure 1 presents a plot of serum 1 ,25(OH)2D concentrations
as functions of the reciprocal of serum creatinine in the 39
patients. There was a progressive decrease in serum
1 ,25(OH)2D with declining renal function. There was a signifi-
7
2
Cr 3.43 0.31 mg/dl
I/Cr 0.43 0.05 (mg/dlY'
Ca 9.4 0.1 mg/dl
P 3.9 0.2mg/di
PTH 2685 808 pg/mI
CT 42 4 pg/mI
1,25(OH)2D 29.4 2.6 pg/mI
BGP 82.5 16.4 pmole/ml
39 cant correlation between these two parameters (r = 0.54, P <
0.001).
The mean serum l,25(OH)2D level was 29.4 2.6 pg/mI. The
females had higher mean values than the males (37.8 4.4 vs.
26.0 3.0 pg/mI). However, the females were also younger
(49.3 4.2 vs. 57.8 2.7 years) and had higher 1/creatinine
values [0.58 0.10 vs. 0,38 0.05 (mg/dlY]. Although there
was a wide variation of 1 ,25(OH)2D levels among individuals
with rather similar degrees of renal failure, 87% of the patients
with 1/creatinine values below 0.25 (mg/di)' had levels of the
hormone below the normal mean. Their levels (19.3 3.5
pg/mi) were also significantly lower than those with 1/creatinine
above 0.25 (mg/dlY' (35.6 3.0 pg/mI, P < 0.002).
Figure 2 demonstrates that 1 ,25(OH)2D levels were signifi-
cantly inversely correlated with serum phosphorus (r =
—0.39,
P < 0.02). However, 1,25(OH)2D levels bore no significant
correlation with serum calcium (r = 0.05). The four patients
who had l/creatinine values below 0.6 (mg/dl) but
1,25(OH)2D levels above 50 pg/mI all had serum phosphorus of
3.6 mg/dl or below.
Figure 3 shows serum 1 ,25(OH)2D level plotted against age.
As previously observed in healthy subjects [28], serum
I ,25(OH)2D was correlated inversely with age in the patients
with renal diseases (r =
—0.33, P < 0.05).
Figure 4 demonstrates the significant inverse correlation
between serum 1 ,25(OH)2D and the logarithm of PTH (r =
—0.47, P < 0.01).
Between serum BGP and 1,25(OH)2D there was a negative
correlation (r =
—0.31), but it was not significant. BGP,
however, did correlate negatively (r = —0.39, P < 0.02) with
1/serum creatinine, and positively with PTH and age (r = 0.57,
P < 0.001 and r = 0.33, P < 0.05, respectively) (Table 3).
Multiple regression analysis was performed to correlate se-
rum l,25(OH)2D with age, 1/serum creatinine, and serum
phosphorus simultaneously. The resultant multiple correlation
coefficient (rm) provided an indication of the confidence of fit of
the regression line from these three variables. The value of this
coefficient was 0.64 (P < 0.001). The l,25(OH)2D value can be
given by the following equation:
1,25(OH)2D = 60.5(±2.7) + 19.6(±l.3) x 1/creatinine (1)
— 5.63(±0.4) x phosphorus — 0.32(±0.03) x age
where l,25(OH)2D is expressed in pg/mi, 1/creatinine in
(mg/dl), phosphorus in mg/dl, and age in years.
Although the predictive value of this equation is not very high
Table 2. Clinical and biochemical measurements in 39 patients (mean
age, 55.4 2.3) with renal diseases6
Mean (± SE)
2
3
4
3
2
3
Abbreviations: Cr, creatinine; Ca, calcium; P, phosphorus; CT,
calcitonin; BGP, bone Gla protein.
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Table 3. Correlations among the biochemical measurements made in 39 patients with renal diseases (see Table 1)
Age 1/Cr Ca P PTH CT l,25(OH)2D BGP
Age 1 —0.28 —0.23 —0.15 0.07 0.08 0.33
1/Cr 1 0.16 —0.34 —0.22 0.54 0.39"
Ca 1 —0.02 —0.15 —0.01 0.05 —0.15
P 1 0.14 —0.06 0.39' 0.26
PTH 1 —0.04 —0.27 0.57'
CT 1 —0.21 —0.25
l,25(OH)2D 1 —0.31
BOP I
E
0)
01.
CI0
t1)
Abbreviations are the same as in Table 2.
P < 0.05
P < 0.02
P < 0.001
E
0)0)
CI0
60
40
20
• •
• .
• . •
•
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•
phorus and age. However, there was a significant inverse
correlation between 1/serum creatinine values and serum phos-
phorus (r = —0.34, P < 0.05), despite the phosphate binding
agents taken by some patients with more advanced renal
failure.
Discussion
= 0.54
P< 0 . 00 1
Fig. 1. Serum 1,25(OH)2D levels as a function of 1/serum creatinine.
Thirteen of 15 patients with 1/creatinine below 0.25 (mg/dlY' had levels
of I ,25(OH)2D below the normal mean. Four patients with 1/creatinine
below 0.6 (mg/dlY' had 1,25(OH)2D levels above 50 pg/mI; these
patients also had low serum phosphorus levels.
We have been able to identify four factors that significantly
• . correlate with serum l,25(OH)2D in renal failure, that is,
1/serum creatinine, phosphorus, log PTH, and age. The correla-
0 02 0.4 016 018 1.0 1.2 tion between serum l,25(OH)2D levels and 1/serum creatinine
1 values was in general agreement with the studies recently1 Creatinine mg dl)
reported in the literature on patients with mild to moderate
renal impairment who did not require dialysis [34—37]. This
observation emphasizes that kidney mass is important in the
synthesis of the hormone. Although there were significant
variations in the values, our patients with 1/serum creatinine
below 0.25 (mg/dl) tended to have subnormal serum concen-
trations of 1 ,25(OH)2D. Christiansen Ct al [37] and Juttman et al
60 [361 had previously found subnormal concentrations of
$ • r .- - 0.39 1 ,25(OH)2D with creatinine clearance below 40 to 50 mI/mm.P :0.02 Our six patients who had relatively mild renal disease with
• 1/serum creatinine > 0.75 (mg/dl)' actually had normal to
40 supranormal l,25(OH)2D levels (mean = 46 4.4 pg/mI). This
• • finding was also in agreement with Slatopolsky's report that
patients with GFR 50 3.7 mi/mm had l,25(OH)2D levels of 44
3.7 pg/ml versus 34 1.5 pg/mi in their normal controls [38].
20 •
This observation was also consistent with the finding that
• • S • intestinal absorption of calcium is normal in patients with serum
•
creatinine below 2.5 mg/dl [39].
In this study serum 1 ,25(OH)2D was observed to be correlat-
I • I ed inversely with age. An earlier study has also found such0 inverse correlation in normal adults [28], It is of interest that
despite the wide variations in renal function at any particular
age which would affect the 1 ,25(OH)2D production, the influ-
ence of age on serum 1,25(OH)2D levels was still apparent.
Serum l,25(OH)2D levels were also inversely correlated with
serum phosphorus. This relationship was previously observed
in patients with primary hyperparathyroidism [28] and rhabdo-
myoiysis-induced acute renal failure [40]. In experimental ani-
mals with normal renal function, dietary phosphorus restriction
increased l,25(OH)2D synthesis [41, 42]. This effect was inde-
pendent of parathyroid hormone and appeared to be mediated
by the phosphorus level in the renal tubular cells [41]. The
inverse correlation between serum 1 ,25(OH)2D and phosphorus
supports the role of phosphorus in the regulation of the former
2 3 4 5 6
Phosphorus. mg/dI
Fig. 2. The relationship between serum I,25(OH)2D levels and serum
phosphorus. The negative correlation is consistent with the inhibitory
effect of phosphorus on renal 1 ,25(OH)2D production.
(rm = 0.64), the slopes and the ranges of each variable provide
an indication of its relative contribution in determining
1 ,25(OH)2D levels.
When correlations between age, 1/serum creatinine, and
serum phosphorus were examined, the following observations
were made. As expected, no significant correlation existed
between 1/serum creatinine and age, nor between serum phos-
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Fig. 4. Correlation of serum 1,25(OH)2D levels with parathyroid hor-
Fig. 3. Correlation of serum 1,25(OH)2D levels with age.
mone levels (in logarithmic scale).
in patients with chronic renal diseases. However, the relation-
ship between serum 1 ,25(OH)2D levels and serum phosphorus
may only be an indirect one. Our data indeed showed serum
phosphorus to be inversely correlated with 1/serum creatinine
as expected (r =
—0.34, P < 0.05). This could imply that
deterioration in renal function caused an increment in serum
phosphorus and simultaneously caused a decrement in
1,25(OH)2D production, such that the serum phosphorus was
related to serum 1 ,25(OH)2D level only indirectly through the
renal function. However, in view of the previously published
experimental data [41, 42], it was likely that serum phosphorus
and renal function individually exerted an influence on
I ,25(OH)D production. Thus, phosphorus restriction is impor-
tant in patients with renal impairment, not only because this
would suppress PTH production [14] but also stimulate
1,25(OH)2D production. This was exemplified by the high
1 ,25(OH)2D levels observed in our patients who demonstrated
poor renal function but low serum phosphorus values.
The relationship between parathyroid hormone and
1,25(OH)2D is complex. In vitro [43] and in vivo [44—46] studies
in animals have demonstrated the stimulatory effect of PTH in
the generation of 1,25(OH)2D. Furthermore, 1,25(OH)2D levels
were high in patients with hyperparathyroidism [28, 47, 48] and
low in patients with hypoparathyroidism [49]. This finding is in
distinct contrast to the patients with renal diseases in our study;
serum 1,25(OH)2D levels were inversely correlated with log
PTH. Thus, the increased levels of PTH in renal failure cannot
prevent the progressive decrease of serum 1 ,25(OH)2D. This is
not surprising because a significant portion of the increased
serum PTH in renal failure is biologically inactive [31]. Howev-
er, it is possible that serum 1 ,25(OH)2D would be even lower in
renal failure if there were no increase in PTH. Some investiga-
tors have also suggested a direct suppressive effect of
l,25(OH)2D on PTH secretion [50, 51], although this conclusion
was not in agreement with certain other studies [52—54]. Wheth-
er this phenomenon was operative in the inverse relationship
between 1 ,25(OH)2D and log PTH remains unclear.
The lack of correlation between 1 ,25(OH)2D and plasma BGP
levels is of interest since the steroid hormone has been reported
to induce secretion of BGP by osteoblast-like cells in vitro [20]
and to cause increased blood levels of BGP in rats [21].
However, since there is a renal component to BGP catabolism,
the variability in renal function in our patients may preclude the
demonstration of such effects. Similarly, the effect of renal
failure on serum CT may obscure any relationship of this
hormone to BGP [17, 18]. The strong correlation between BGP
and PTH levels may reflect a functional relationship between
these two peptides or it may merely reflect their serum accumu-
lation in renal failure.
Treatment of patients with symptomatic renal osteodys-
trophy with 1,25(OH)2D has resulted in decreased bone pain, a
decrease in plasma alkaline phosphatase and PTH levels, and
an improvement in bone histology. Some investigators have,
however, reported further deterioration of renal function in
patients with renal insufficiency who were treated with
1,25(OH)2D [55]. The guideline for 1,25(OH)2D prophylaxis in
patients with renal insufficiency has not been firmly estab-
lished. From our data it appeared that most patients with
1/serum creatinine values below 0.25 (mg/dlY' exhibited
1,25(OH)2D levels below the normal mean, and mild renal
insufficiency with 1/serum creatinine values greater than 0.75
(mg/dlY' was associated with normal or supranormal
1 ,25(OH)2D levels. Despite the statistically significant correla-
tion, serum 1,25(OH)2D levels cannot be estimated from serum
creatinine alone. Other factors should be considered in the
prophylaxis with l,25(OH)2D in patients with chronic renal
insufficiency.
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